Oxidative stress and endothelial dysfunction: Therapeutic implications

References

• Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673–8.
   PubMed Web of Science ®Google Scholar
• Lippincott MF, Carlow A, Desai A, Blum A, Rodrigo M, Patibandla S, . Relation of endothelial function to cardiovascular risk in women with sedentary occupations and without known cardiovascular disease. Am J Cardiol. 2008; 102:348–52.
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the ‘vulnerable’ patient. Circulation. 2004;110:1926–32.
   PubMed Web of Science ®Google Scholar
• Heitzer T, Baldus S, von Kodolitsch Y, Rudolph V, Meinertz T. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol. 2005;25:1174–9.
   PubMed Web of Science ®Google Scholar
• Akcakoyun M, Kargin R, Tanalp AC, Pala S, Ozveren O, Akcay M, . Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events and restenosis in patients undergoing coronary stent implantation: a prospective study. Coron Artery Dis. 2008;19:337–43.
   PubMed Web of Science ®Google Scholar
• Thanyasiri P, Kathir K, Celermajer DS, Adams MR. Endothelial dysfunction and restenosis following percutaneous coronary intervention. Int J Cardiol. 2007;119:362–7.
   PubMedGoogle Scholar
• Kitta Y, Nakamura T, Kodama Y, Takano H, Umetani K, Fujioka D, . Endothelial vasomotor dysfunction in the brachial artery is associated with late in-stent coronary restenosis. J Am Coll Cardiol. 2005;46:648–55.
   PubMed Web of Science ®Google Scholar
• Munzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med. 2008;40:180–96.
   PubMed Web of Science ®Google Scholar
• Herrmann J, Lerman A. The endothelium—the cardiovascular health barometer. Herz. 2008;33:343–53.
   PubMed Web of Science ®Google Scholar
• Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation. 2002;106:640–2.
   PubMed Web of Science ®Google Scholar
• Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271(5 Pt 1):C1424–37.
   Google Scholar
• Munzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. Herz. 1997;22:158–72.
   PubMed Web of Science ®Google Scholar
• Boulden BM, Widder JD, Allen JC, Smith DA, Al-Baldawi RN, Harrison DG, . Early determinants of H2O2-induced endothelial dysfunction. Free Radic Biol Med. 2006;41:810–7.
   PubMed Web of Science ®Google Scholar
• Hink U, Oelze M, Kolb P, Bachschmid M, Zou MH, Daiber A, . Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol. 2003;42:1826–34.
   PubMed Web of Science ®Google Scholar
• Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003;4:41–51.
   PubMed Web of Science ®Google Scholar
• Luo Z, Teerlink T, Griendling K, Aslam S, Welch WJ, Wilcox CS. Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells. Hypertension. 2010;56:498–504.
   PubMed Web of Science ®Google Scholar
• Cooke MS, Evans MD, Podmore ID, Herbert KE, Mistry N, Mistry P, . Novel repair action of vitamin C upon in vivo oxidative DNA damage. FEBS Lett. 1998;439:363–7.
   PubMed Web of Science ®Google Scholar
• Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem. 2003;278:22546–54.
   PubMed Web of Science ®Google Scholar
• Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol. 2002;282:H2167–72.
   PubMed Web of Science ®Google Scholar
• Moat SJ, Clarke ZL, Madhavan AK, Lewis MJ, Lang D. Folic acid reverses endothelial dysfunction induced by inhibition of tetrahydrobiopterin biosynthesis. Eur J Pharmacol. 2006;530:250–8.
   PubMedGoogle Scholar
• Ye Z, Song H. Antioxidant vitamins intake and the risk of coronary heart disease: meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil. 2008;15:26–34.
   PubMed Web of Science ®Google Scholar
• Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993;342:1007–11.
   PubMed Web of Science ®Google Scholar
• Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, . Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr. 2007;85:895–909.
   PubMed Web of Science ®Google Scholar
• Wright ME, Lawson KA, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, . Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr. 2006; 84:1200–7.
   PubMed Web of Science ®Google Scholar
• Loria CM, Klag MJ, Caulfield LE, Whelton PK. Vitamin C status and mortality in US adults. Am J Clin Nutr. 2000; 72:139–45.
   PubMed Web of Science ®Google Scholar
• Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–6.
   PubMed Web of Science ®Google Scholar
• Salonen RM, Nyyssonen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH, . Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation. 2003;107:947–53.
   PubMed Web of Science ®Google Scholar
• Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, . Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst. 2009;101:507–18.
   PubMed Web of Science ®Google Scholar
• Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, . Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294: 56–65.
   PubMed Web of Science ®Google Scholar
• Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017–23.
   PubMed Web of Science ®Google Scholar
• Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, . Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–88.
   PubMed Web of Science ®Google Scholar
• Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.
   PubMed Web of Science ®Google Scholar
• Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, . Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293:1338–47.
   PubMed Web of Science ®Google Scholar
• Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs DR Jr. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr. 2004;80:1194–200.
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842–57.
   PubMed Web of Science ®Google Scholar
• Michalska M, Gluba A, Mikhailidis DP, Nowak P, Bielecka-Dabrowa A, Rysz J, . The role of polyphenols in cardiovascular disease. Med Sci Monit. 2010;16: RA110–9.
   PubMed Web of Science ®Google Scholar
• Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, . Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:38–50.
   PubMed Web of Science ®Google Scholar
• Tomasian D, Keaney JF, Vita JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovasc Res. 2000;47:426–35.
   PubMedGoogle Scholar
• Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, . Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140: 533–7.
   PubMed Web of Science ®Google Scholar
• Gori T, Parker JD. Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs. J Am Coll Cardiol. 2008;52:251–4.
   PubMedGoogle Scholar
• Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, . Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A. 2007;104:8749–54.
   PubMed Web of Science ®Google Scholar
• Hara S, Mizukami H, Mukai T, Kurosaki K, Kuriiwa F, Endo T. Involvement of extracellular ascorbate and iron in hydroxyl radical generation in rat striatum in carbon monoxide poisoning. Toxicology. 2009;264:69–73.
   PubMed Web of Science ®Google Scholar
• Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785–92.
   PubMed Web of Science ®Google Scholar
• Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, . Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47: 1108–16.
   PubMed Web of Science ®Google Scholar
• Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med. 2001;11:93–102.
   PubMed Web of Science ®Google Scholar
• Kleschyov AL, Oelze M, Daiber A, Huang Y, Mollnau H, Schulz E, . Does nitric oxide mediate the vasodilator activity of nitroglycerin? Circ Res. 2003;93:e104–12.
   PubMed Web of Science ®Google Scholar
• Kojda G, Noack E. Effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate in experimental atherosclerosis. Agents Actions Suppl. 1995;45:201–6.
   PubMedGoogle Scholar
• Kojda G, Stein D, Kottenberg E, Schnaith EM, Noack E. In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 1995;25:763–73.
   PubMed Web of Science ®Google Scholar
• Chirkov YY, Chirkova LP, Horowitz JD. Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am J Cardiol. 1997;80:128–31.
   PubMedGoogle Scholar
• Wenzel P, Mollnau H, Oelze M, Schulz E, Wickramanayake JM, Muller J, . First evidence for a crosstalk between mitochondrial and NADPH oxidase–derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal. 2008;10:1435–47.
   PubMed Web of Science ®Google Scholar
• Gori T, Burstein JM, Ahmed S, Miner SE, Al-Hesayen A, Kelly S, . Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation. 2001;104:1119–23.
   PubMed Web of Science ®Google Scholar
• Gori T, Mak SS, Kelly S, Parker JD. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol. 2001;38: 1096–101.
   PubMed Web of Science ®Google Scholar
• Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618–28.
   PubMed Web of Science ®Google Scholar
• Gori T, Daiber A. Non-hemodynamic effects of organic nitrates and the distinctive characteristics of pentaerithrityl tetranitrate. Am J Cardiovasc Drugs. 2009;9:7–15.
   PubMedGoogle Scholar
• Parker JO, Parker JD, Caldwell RW, Farrell B, Kaesemeyer WH. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol. 2002;39:1199–203.
   PubMed Web of Science ®Google Scholar
• Wong PC, Hart SD, Duncia JV, Timmermans PB. Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. Eur J Pharmacol. 1991;202: 323–30.
   PubMed Web of Science ®Google Scholar
• Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, . Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation. 1999;100:1223–9.
   PubMed Web of Science ®Google Scholar
• Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res. 1998;83:952–9.
   PubMed Web of Science ®Google Scholar
• Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, . Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027–33.
   PubMed Web of Science ®Google Scholar
• Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, . Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000;86:E85–90.
   PubMed Web of Science ®Google Scholar
• Mombouli JV, Vanhoutte PM. Kinins and the vascular actions of converting enzyme inhibitors. Curr Opin Nephrol Hypertens. 1994;3:481–4.
   PubMedGoogle Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9.
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–57.
   PubMed Web of Science ®Google Scholar
• West of Scotland Coronary Prevention Study: implications for clinical practice. The WOSCOPS Study Group. Eur Heart J. 1996;17:163–4.
   PubMedGoogle Scholar
• Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
   PubMed Web of Science ®Google Scholar
• Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol. 2005;16:624–9.
   PubMed Web of Science ®Google Scholar
• Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, . Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687–92.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 2010;74:818–26.
   PubMed Web of Science ®Google Scholar
• Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, . Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356–63.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, . Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344: 1959–65.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230–5.
   PubMed Web of Science ®Google Scholar
• Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol. 2004;94:157–61.
   PubMed Web of Science ®Google Scholar
• Valkonen VP, Laakso J, Paiva H, Lehtimaki T, Lakka TA, Isomustajarvi M, . Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler Suppl. 2003;4:19–22.
   PubMedGoogle Scholar
• Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, . Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300–5.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15:467–78.
   PubMed Web of Science ®Google Scholar
• Riccioni G. Statins and carotid intima-media thickness reduction: an up-to-date review. Curr Med Chem. 2009;16: 1799–805.
   PubMedGoogle Scholar
• Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, . Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM. 2010 Oct 7 (Epub ahead of print).
   Google Scholar
• Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol. 2010;105(1 Suppl):21A–29A.
   Google Scholar
• Cangemi R, Angelico F, Loffredo L, Del Ben M, Pignatelli P, Martini A, . Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. Free Radic Biol Med. 2007;43:853–9.
   PubMedGoogle Scholar
• Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Franzoni F, Taddei S, . Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens. 2007; 20:392–7.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Giannopoulos D, Dalais FS, Hodgson J, McGrath BP. Randomised, controlled, cross-over trial of soy protein with isoflavones on blood pressure and arterial function in hypertensive subjects. J Am Coll Nutr. 2006; 25:533–40.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Sherwood RA, Swift CG, Jackson SH. Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial. J Intern Med. 2002;252:497–503.
   PubMed Web of Science ®Google Scholar
• Young JM, Shand BI, McGregor PM, Scott RS, Frampton CM. Comparative effects of enzogenol and vitamin C supplementation versus vitamin C alone on endothelial function and biochemical markers of oxidative stress and inflammation in chronic smokers. Free Radic Res. 2006;40: 85–94.
   PubMed Web of Science ®Google Scholar
• Takase B, Etsuda H, Matsushima Y, Ayaori M, Kusano H, Hamabe A, . Effect of chronic oral supplementation with vitamins on the endothelial function in chronic smokers. Angiology. 2004;55:653–60.
   PubMedGoogle Scholar
• Neunteufl T, Priglinger U, Heher S, Zehetgruber M, Soregi G, Lehr S, . Effects of vitamin E on chronic and acute endothelial dysfunction in smokers. J Am Coll Cardiol. 2000;35:277–83.
   PubMed Web of Science ®Google Scholar
• Heiss C, Kleinbongard P, Dejam A, Perre S, Schroeter H, Sies H, . Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol. 2005;46:1276–83.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Arya R, Ford E, Asonganyi B, Sherwood RA, Ouldred E, . Effects of folic acid supplementation on inflammatory and thrombogenic markers in chronic smokers. A randomised controlled trial. Thromb Res. 2003; 110:13–17.
   PubMed Web of Science ®Google Scholar
• Antoniades C, Tousoulis D, Tentolouris C, Toutouza M, Marinou K, Goumas G, . Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost. 2003; 89:990–5.
   PubMed Web of Science ®Google Scholar
• Thorne S, Mullen MJ, Clarkson P, Donald AE, Deanfield JE. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol. 1998;32:110–6.
   PubMed Web of Science ®Google Scholar
• Skyrme-Jones RA, O'Brien RC, Berry KL, Meredith IT. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. J Am Coll Cardiol. 2000;36:94–102.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Evans LM, Ellis GR, Khan N, Morris K, Jackson SK, . Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type 2 diabetes. Diabet Med. 2006;23: 258–64.
   PubMed Web of Science ®Google Scholar
• Economides PA, Khaodhiar L, Caselli A, Caballero AE, Keenan H, Bursell SE, . The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. Diabetes. 2005;54:204–11.
   PubMed Web of Science ®Google Scholar
• Pena AS, Wiltshire E, Gent R, Hirte C, Couper J. Folic acid improves endothelial function in children and adolescents with type 1 diabetes. J Pediatr. 2004;144:500–4.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Sherwood RA, Asonganyi B, Swift CG, Thomas S, Jackson SH. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens. 2005;18(2 Pt 1):220–6.
   PubMedGoogle Scholar
• van Etten RW, de Koning EJ, Verhaar MC, Gaillard CA, Rabelink TJ. Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia. 2002;45:1004–10.
   PubMed Web of Science ®Google Scholar
• Hamilton SJ, Chew GT, Watts GF. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care. 2009;32:810–2.
   PubMed Web of Science ®Google Scholar
• Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA. Folic acid improves endothelial dysfunction in type 2 diabetes—an effect independent of homocysteine-lowering. Vasc Med. 2006;11:101–9.
   PubMed Web of Science ®Google Scholar
• Regensteiner JG, Popylisen S, Bauer TA, Lindenfeld J, Gill E, Smith S, . Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med. 2003;8:169–75.
   PubMed Web of Science ®Google Scholar
• Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter MC, Paul SM, . Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation. 2003;108:1059–63.
   PubMed Web of Science ®Google Scholar
• Neunteufl T, Kostner K, Katzenschlager R, Zehetgruber M, Maurer G, Weidinger F. Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol. 1998;32:711–6.
   PubMed Web of Science ®Google Scholar
• Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 1998;97:237–41.
   PubMed Web of Science ®Google Scholar
• Hamabe A, Takase B, Uehata A, Kurita A, Ohsuzu F, Tamai S. Impaired endothelium-dependent vasodilation in the brachial artery in variant angina pectoris and the effect of intravenous administration of vitamin C. Am J Cardiol. 2001;87:1154–9.
   PubMedGoogle Scholar
• Cangemi R, Loffredo L, Carnevale R, Perri L, Patrizi MP, Sanguigni V, . Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J. 2008;29:54–62.
   PubMed Web of Science ®Google Scholar
• Chan YH, Lau KK, Yiu KH, Li SW, Chan HT, Tam S, . Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am J Clin Nutr. 2007;86:938–45.
   PubMedGoogle Scholar
• Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol. 2000;36:758–65.
   PubMed Web of Science ®Google Scholar
• Moens AL, Claeys MJ, Wuyts FL, Goovaerts I, Van Hertbruggen E, Wendelen LC, . Effect of folic acid on endothelial function following acute myocardial infarction. Am J Cardiol. 2007;99:476–81.
   PubMed Web of Science ®Google Scholar
• Doshi S, McDowell I, Moat S, Lewis M, Goodfellow J. Folate improves endothelial function in patients with coronary heart disease. Clin Chem Lab Med. 2003;41: 1505–12.
   PubMed Web of Science ®Google Scholar
• Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, . Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation. 2002;105:22–6.
   PubMed Web of Science ®Google Scholar
• Stanger O, Semmelrock HJ, Wonisch W, Bos U, Pabst E, Wascher TC. Effects of folate treatment and homocysteine lowering on resistance vessel reactivity in atherosclerotic subjects. J Pharmacol Exp Ther. 2002;303:158–62.
   PubMedGoogle Scholar
• Heiss C, Jahn S, Taylor M, Real WM, Angeli FS, Wong ML, . Improvement of endothelial function with dietary flavanols is associated with mobilization of circulating angiogenic cells in patients with coronary artery disease. J Am Coll Cardiol. 2010;56:218–24.
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Antoniades C, Vassiliadou C, Toutouza M, Pitsavos C, Tentolouris C, . Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail. 2005;7:1126–32.
   PubMed Web of Science ®Google Scholar
• Ellis GR, Anderson RA, Chirkov YY, Morris-Thurgood J, Jackson SK, Lewis MJ, . Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J Cardiovasc Pharmacol. 2001;37:564–70.
   PubMedGoogle Scholar
• Tousoulis D, Xenakis C, Tentolouris C, Davies G, Antoniades C, Crake T, . Effects of vitamin C on intracoronary L-arginine dependent coronary vasodilatation in patients with stable angina. Heart. 2005;91:1319–23.
   PubMed Web of Science ®Google Scholar
• Grebe M, Eisele HJ, Weissmann N, Schaefer C, Tillmanns H, Seeger W, . Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med. 2006;173:897–901.
   PubMed Web of Science ®Google Scholar
• Tam LS, Li EK, Leung VY, Griffith JF, Benzie IF, Lim PL, . Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double blind, placebo controlled pilot study. J Rheumatol. 2005;32:275–82.
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Cupisti A, Huang Y, Mattei P, Cardinal H, Favilla S, . Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol. 2004;17:512–9.
   PubMedGoogle Scholar
• Cross JM, Donald AE, Nuttall SL, Deanfield JE, Woolfson RG, Macallister RJ. Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. Kidney Int. 2003;63:1433–42.
   PubMed Web of Science ®Google Scholar
• Nanayakkara PW, van Guldener C, ter Wee PM, Scheffer PG, van Ittersum FJ, Twisk JW, . Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med. 2007;167:1262–70.
   PubMedGoogle Scholar
• Gori T, Saunders L, Ahmed S, Parker JD. Effect of folic acid on nitrate tolerance in healthy volunteers: differences between arterial and venous circulation. J Cardiovasc Pharmacol. 2003;41:185–90.
   PubMedGoogle Scholar
• Thomas GR, DiFabio JM, Gori T, Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol. 2007;49:1289–95.
   PubMed Web of Science ®Google Scholar
• Dragoni S, Gori T, Di Stolfo G, Sicuro S, Forconi S, Parker JD. Folic acid does not limit endothelial dysfunction induced by ischemia and reperfusion: a human study. J Cardiovasc Pharmacol. 2005;46:494–7.
   PubMedGoogle Scholar
• Woodman RJ, Celermajer DE, Thompson PL, Hung J. Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects. Clin Sci (Lond). 2004; 106:353–8.
   PubMedGoogle Scholar
• Farouque HM, Leung M, Hope SA, Baldi M, Schechter C, Cameron JD, . Acute and chronic effects of flavanol-rich cocoa on vascular function in subjects with coronary artery disease: a randomized double-blind placebo-controlled study. Clin Sci (Lond). 2006;111:71–80.
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, . Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008;300:2123–33.
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, . Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–9.
   PubMed Web of Science ®Google Scholar
• Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, . Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150–5.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154–60.
   PubMed Web of Science ®Google Scholar
• Cook NR, Albert CM, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, . A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med. 2007;167:1610–8.
   PubMed Web of Science ®Google Scholar
• Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, . Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA. 2010;303:2486–94.
   PubMed Web of Science ®Google Scholar
• Ebbing M, Bonaa KH, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, . Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials. J Intern Med. 2010;268:367–82.
   PubMed Web of Science ®Google Scholar
• Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, . Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300:795–804.
   PubMed Web of Science ®Google Scholar
• Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, . Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299:2027–36.
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, . Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, Liu CR, . Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation. 2002;106:1453–9.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maki KC, Dicklin MR, Feinstein SB, Witchger M, Bell M, . Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol. 2009;104:936–42.
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, Dornfeld L, . Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004;23:423–33.
   PubMed Web of Science ®Google Scholar
• Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, . Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432–40.
   PubMed Web of Science ®Google Scholar
• Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, . Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37:1933–40.
   PubMed Web of Science ®Google Scholar
• Napoli C, Bruzzese G, Ignarro LJ, Crimi E, de Nigris F, Williams-Ignarro S, . Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J. 2008;156:1154.e1–8.
   PubMed Web of Science ®Google Scholar
• Hosomi N, Mizushige K, Ohyama H, Takahashi T, Kitadai M, Hatanaka Y, . Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke. 2001;32:1539–45.
   PubMed Web of Science ®Google Scholar
• Ono H, Minatoguchi S, Watanabe K, Yamada Y, Mizukusa T, Kawasaki H, . Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res. 2008;31:271–9.
   PubMedGoogle Scholar
• Zanchetti A, Crepaldi G, Bond MG, Gallus G, Veglia F, Mancia G, . Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS—a randomized double-blind trial. Stroke. 2004; 35:2807–12.
   PubMed Web of Science ®Google Scholar